Analysis of V2 Antibody Responses Induced in Vaccinees in the ALVAC/AIDSVAX HIV-1 Vaccine Efficacy Trial

The RV144 clinical trial of a prime/boost immunizing regimen using recombinant canary pox (ALVAC-HIV) and two gp120 proteins (AIDSVAX B and E) was previously shown to have a 31.2% efficacy rate. Plasma specimens from vaccine and placebo recipients were used in an extensive set of assays to identify...

Descripción completa

Detalles Bibliográficos
Autores principales: Zolla-Pazner, Susan, deCamp, Allan C., Cardozo, Timothy, Karasavvas, Nicos, Gottardo, Raphael, Williams, Constance, Morris, Daryl E., Tomaras, Georgia, Rao, Mangala, Billings, Erik, Berman, Phillip, Shen, Xiaoying, Andrews, Charla, O'Connell, Robert J., Ngauy, Viseth, Nitayaphan, Sorachai, de Souza, Mark, Korber, Bette, Koup, Richard, Bailer, Robert T., Mascola, John R., Pinter, Abraham, Montefiori, David, Haynes, Barton F., Robb, Merlin L., Rerks-Ngarm, Supachai, Michael, Nelson L., Gilbert, Peter B., Kim, Jerome H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3547933/
https://www.ncbi.nlm.nih.gov/pubmed/23349725
http://dx.doi.org/10.1371/journal.pone.0053629

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3547933/
https://www.ncbi.nlm.nih.gov/pubmed/23349725
http://dx.doi.org/10.1371/journal.pone.0053629

Ejemplares similares